Acromegaly clinical trials

Explore recruiting acromegaly clinical trials.

Recruiting acromegaly studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Acromegaly trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose Range-finding, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALXN2420, a Growth Hormone Receptor Antagonist, Administered Subcutaneously in Combination with Somatostatin Analogs in Adult Participants with Acromegaly

Lithuania, Romania, Denmark, Italy, Hungary, Poland +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Non-pharmacologically Treated Acromegaly (PATHFNDR-2)

Germany, France, Hungary, Poland, Italy, Bulgaria +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An open label, long-term extension study to evaluate the safety and efficacy of CRN00808 in subjects with acromegaly (ACROBAT ADVANCE)

Hungary, Greece, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, open-label, single-arm, multi-center trial to assess the long-term safety of octreotide subcutaneous depot (CAM2029) in patients with acromegaly

Hungary, Germany, Spain, Italy, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Acromegaly Treated with Long-acting Somatostatin Receptor Ligands

Belgium, France, Hungary, Bulgaria, Poland, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A single and multiple ascending dose study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZP-3813, a growth hormone antagonist, in healthy subjects

Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Acromegaly trials by city

Acromegaly in Toronto Acromegaly in Vancouver Acromegaly in Montreal Acromegaly in Calgary Acromegaly in Edmonton Acromegaly in Ottawa Acromegaly in Winnipeg Acromegaly in Quebec City Acromegaly in Hamilton Acromegaly in Kitchener Acromegaly in London Acromegaly in Halifax Acromegaly in New York Acromegaly in Los Angeles Acromegaly in Chicago Acromegaly in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease